204 related articles for article (PubMed ID: 31937922)
21. Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival.
Helo P; Cronin AM; Danila DC; Wenske S; Gonzalez-Espinoza R; Anand A; Koscuiszka M; Väänänen RM; Pettersson K; Chun FK; Steuber T; Huland H; Guillonneau BD; Eastham JA; Scardino PT; Fleisher M; Scher HI; Lilja H
Clin Chem; 2009 Apr; 55(4):765-73. PubMed ID: 19233911
[TBL] [Abstract][Full Text] [Related]
22. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.
de Bono JS; Scher HI; Montgomery RB; Parker C; Miller MC; Tissing H; Doyle GV; Terstappen LW; Pienta KJ; Raghavan D
Clin Cancer Res; 2008 Oct; 14(19):6302-9. PubMed ID: 18829513
[TBL] [Abstract][Full Text] [Related]
23. Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation.
Das A; Kunkel M; Joudeh J; Dicker DT; Scicchitano A; Allen JE; Sarwani N; Yang Z; Kaifi J; Zhu J; Liao J; El-Deiry WS
Cancer Biol Ther; 2015; 16(5):709-13. PubMed ID: 25806877
[TBL] [Abstract][Full Text] [Related]
24. Detection of extracellular vesicles in plasma and urine of prostate cancer patients by flow cytometry and surface plasmon resonance imaging.
Rikkert LG; de Rond L; van Dam A; van Leeuwen TG; Coumans FAW; de Reijke TM; Terstappen LWMM; Nieuwland R
PLoS One; 2020; 15(6):e0233443. PubMed ID: 32497056
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Significance of Gene Expression and DNA Methylation Markers in Circulating Tumor Cells and Paired Plasma Derived Exosomes in Metastatic Castration Resistant Prostate Cancer.
Zavridou M; Strati A; Bournakis E; Smilkou S; Tserpeli V; Lianidou E
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33668490
[TBL] [Abstract][Full Text] [Related]
26. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
[TBL] [Abstract][Full Text] [Related]
28. Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.
Lorente D; Olmos D; Mateo J; Dolling D; Bianchini D; Seed G; Flohr P; Crespo M; Figueiredo I; Miranda S; Scher HI; Terstappen LWMM; de Bono JS
Ann Oncol; 2018 Jul; 29(7):1554-1560. PubMed ID: 29741566
[TBL] [Abstract][Full Text] [Related]
29. Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial.
Gennari A; Foca F; Zamarchi R; Rocca A; Amadori D; De Censi A; Bologna A; Cavanna L; Gianni L; Scaltriti L; Rossi E; Facchinetti A; Martini V; Bruzzi P; Nanni O
Breast Cancer Res Treat; 2020 May; 181(1):61-68. PubMed ID: 32200486
[TBL] [Abstract][Full Text] [Related]
30. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
[TBL] [Abstract][Full Text] [Related]
31. Circulating tumour cells and hypercoagulability: a lethal relationship in metastatic breast cancer.
Kirwan CC; Descamps T; Castle J
Clin Transl Oncol; 2020 Jun; 22(6):870-877. PubMed ID: 31473984
[TBL] [Abstract][Full Text] [Related]
32. Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
De Laere B; Oeyen S; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; Van Kerckhove P; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff I; van Dam V; Brouwer A; van Dam PJ; Van den Eynden G; Rutten A; Sleijfer S; Vandebroek J; Van Laere S; Dirix L
Prostate; 2018 May; 78(6):435-445. PubMed ID: 29431193
[TBL] [Abstract][Full Text] [Related]
33. Expression pattern of androgen receptors, AR-V7 and AR-567es, in circulating tumor cells and paired plasma-derived extracellular vesicles in metastatic castration resistant prostate cancer.
Strati A; Zavridou M; Bournakis E; Mastoraki S; Lianidou E
Analyst; 2019 Nov; 144(22):6671-6680. PubMed ID: 31596277
[TBL] [Abstract][Full Text] [Related]
34. Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer.
de Kruijff IE; Sieuwerts AM; Onstenk W; Jager A; Hamberg P; de Jongh FE; Smid M; Kraan J; Timmermans MA; Martens JWM; Sleijfer S
Int J Cancer; 2019 Aug; 145(4):1083-1089. PubMed ID: 30761532
[TBL] [Abstract][Full Text] [Related]
35. Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration-sensitive prostate cancer.
Yang YJ; Kong YY; Li GX; Wang Y; Ye DW; Dai B
BJU Int; 2019 Aug; 124(2):258-267. PubMed ID: 30536520
[TBL] [Abstract][Full Text] [Related]
36. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience.
Olmos D; Arkenau HT; Ang JE; Ledaki I; Attard G; Carden CP; Reid AH; A'Hern R; Fong PC; Oomen NB; Molife R; Dearnaley D; Parker C; Terstappen LW; de Bono JS
Ann Oncol; 2009 Jan; 20(1):27-33. PubMed ID: 18695026
[TBL] [Abstract][Full Text] [Related]
37. Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer.
Androulakis N; Agelaki S; Perraki M; Apostolaki S; Bozionelou V; Pallis A; Kalbakis K; Xyrafas A; Mavroudis D; Georgoulias V
Br J Cancer; 2012 Jun; 106(12):1917-25. PubMed ID: 22669159
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
[TBL] [Abstract][Full Text] [Related]
39. Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: a meta-analysis and systematic review.
Yang C; Zou K; Zheng L; Xiong B
BMC Cancer; 2017 Nov; 17(1):725. PubMed ID: 29115932
[TBL] [Abstract][Full Text] [Related]
40. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer.
Mu Z; Wang C; Ye Z; Rossi G; Sun C; Li L; Zhu Z; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2017 Oct; 165(3):733-741. PubMed ID: 28687903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
